Akero Therapeutics Inc
NASDAQ:AKRO

Watchlist Manager
Akero Therapeutics Inc Logo
Akero Therapeutics Inc
NASDAQ:AKRO
Watchlist
Price: 54.65 USD
Market Cap: 4.5B USD

Operating Margin

0%
Current
No historical data
Comparison unavailable

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
0%
=
$0
/
$0

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
0%
=
$0
/
$0

Peer Comparison

Country Company Market Cap Operating
Margin
US
Akero Therapeutics Inc
NASDAQ:AKRO
4.4B USD
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
378.3B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
178.1B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
154.2B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
112.3B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
77.3B USD
Loading...
AU
CSL Ltd
ASX:CSL
85.3B AUD
Loading...
NL
argenx SE
XBRU:ARGX
41.7B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
46.9B USD
Loading...
No Stocks Found

Market Distribution

Not Available
No Country distribution data available for this multiple

Akero Therapeutics Inc
Glance View

Market Cap
4.5B USD
Industry
Biotechnology

Akero Therapeutics Inc. is a biopharmaceutical company deeply anchored in the quest to tackle some of the most pressing challenges in healthcare through its innovative approach to chronic liver diseases. Founded with the vision of transforming treatment paradigms, Akero is primarily focused on developing therapies for non-alcoholic steatohepatitis (NASH), a serious liver condition that currently lacks FDA-approved treatments. The company’s lead asset, EFX, is a precision-engineered FGF21 analog that targets the underlying causes of NASH by improving lipid and glucose metabolism, reducing inflammation, and reversing fibrosis. This drug candidate encapsulates the company’s mission of leveraging scientific innovation to address significant unmet medical needs. Akero’s business model is built on pioneering research, which it hopes will translate into lucrative commercial opportunities. The company invests heavily in clinical trials to demonstrate the efficacy of its therapies, aiming to secure regulatory approvals that pave the path for market entry. By advancing EFX through various phases of clinical studies, Akero strives to establish a foothold in the burgeoning NASH market, projected to become a multi-billion dollar industry. Revenues are anticipated from eventual drug sales, partnered collaborations, and potentially out-licensing deals. In essence, Akero’s approach is a calculated blend of scientific exploration and strategic market navigation, where success hinges on both innovative drug development and adept management of regulatory and commercial pathways.

AKRO Intrinsic Value
Not Available
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Back to Top